Showing posts sorted by date for query psychedelic. Sort by relevance Show all posts
Showing posts sorted by date for query psychedelic. Sort by relevance Show all posts

Monday, October 05, 2026

Explore the Irish cave where Celts gathered for year's shortest day

05.10.2026, DPA

Photo: Daniela David/dpa-tmn

Older than Stonehenge and the Egyptian pyramids, people used to celebrate the solstice in the mythic Newgrange burial complex. It's a spiritual spot where energy flows, one of many in Ireland, from the Atlantic Coast to wild herbal walks and magic fairy trees.

By Daniela David, dpa

It's pitch black here inside the stone burial chamber and we feel uneasy as we gaze spellbound into the darkness.

But people sat here doing the same thing 5,000 years ago, as they gathered to mark the shortest day of the year in the depths of the misty Irish winter.

Suddenly, a beam of amber light shoots through the chamber, illuminating zigzag lines, diamonds and spirals on the stone walls.

A magical moment, even if created by human hands. "The sun god enters, bringing light and hope," says our guide, Gráinne Downey, inside the megalithic passage tomb at Newgrange. She fiddles with the controls for the electric lighting.

"On our tours, we simulate a unique phenomenon that has been taking place here in real life every year for millennia, on December 21 at 8:58 am."

For, at the exact moment of the winter solstice, the morning light streams through a crack in the wall and illuminates the burial chamber, hidden deep within the huge mound, for 17 minutes.

Some 200,000 tonnes of stone have been piled up there to form a vault – not for the claustrophobic. Only the 1960s that archaeologists began to study this complex Neolithic structure.

Newgrange has been a UNESCO World Heritage Site since 1993, as part of the Brú na Bóinne complex of prehistoric sacred sites in County Meath, in the central east of the island.

Belief in the Otherworld

"The Newgrange burial complex is older than the famous Stonehenge in England and even older than the Egyptian pyramids," says guide Peter Cole.

He strides towards the grass-covered, circular burial mounds at neighbouring Knowth, which also forms part of the Brú na Bóinne complex. As if in an ancient art gallery, huge sandstone blocks line the sacred sites. Spiral patterns are incised on them, giving a psychedelic feel.

"The power places of the ancient deities are still at work," says high priestess Treasa Kerrigan with conviction, at another sacred site, some 20 kilometres south-west of Brú na Bóinne.

Her long hair blows in the wind as she leads a group of visitors up the sacred hill of Tara. This former pagan place of worship was the seat of the High Kings of Ireland, a place of power and mystery.

At the very top, the King’s Stone, known as Lia Fáil, soars into the sky. Tourists touch the granite pillar and walk round it three times with their eyes closed, as the ritual goes, in order to feel the stone’s energy. Not everyone succeeds in doing so.

Many of the people here trust in the "Otherworld," where gods, elves and spirits are said to dwell. They see fairy trees – usually striking hawthorn bushes by the roadside – which are gateways to this non-material parallel world. Some in Ireland also say that felling such a magical tree brings terrible misfortune.

"Spiritually sensitive people from all over the world feel an inner peace at our places of power, as if they were connected to something greater," says Kerrigan. One such area is the Hill of Uisneach in County Westmeath, some 80 kilometres further west, which plays a central role on this tour of places of power.

This ritual gathering place is regarded as the mythical centre of Ireland. Celts used to celebrate fire festivals here.

Speaking prayers in Irish, the spiritual guide calls upon the gods of the Otherworld, whose signs she says she has personally witnessed.

She lights a fire.

A place of power with organic vegetables

A German couple, Gaby and Hans Wieland, came here in 1985 and created a place of power of a different sort in Ballincastle, County Sligo on the north-western coast of the island of Ireland.

They grow organic fruit and vegetables on their farm. "We feel the energy of nature in Ireland," says Hans Wieland. Herbs give off their scent in their lush garden, while aubergines, peppers, peach and tomato plants thrive in the greenhouse.

On a wild herb walk, herbalist Gaby Wieland plucks a much-maligned plant, a nettle. "Its seeds are extremely rich in energy!" she says. At her kitchen garden school, Neantóg which is Gaelic for "stinging nettle," she teaches people how to harness the power of wild plants, drawing on ancient Irish knowledge of nature.

Plenty more places provide energy, though not necessarily linked to the ancient places of power, such as the Kilcullen Seaweed Bath in Enniscrone on the Atlantic Ocean.

In the historic bathing establishment, bath attendant Brenda Smith scatters seaweed into ceramic bathtubs dating from 1912 and lets hot seawater run in.

"Our oldest customer is 96 years old," she says. "He swears by the healing power of the iodine-rich seaweed." And as soon as you immerse yourself in the silky water and pull the seaweed over you like a soft blanket, your worries do indeed seem to vanish.

A little further along the Atlantic coast, where Mount Knocknarea rises, and we are back in the land of myth. Visible from afar, we see a caern, the legendary tomb of Queen Maeve.

“The Celtic goddess Maeve is described as a relentless warrior who, on top of that, could have any man she wanted,” says Fiona Stapelton, an Irishwoman who guides hikers through a heathland and marsh landscape.

We head up the 327-metre mountain. At the summit, the wind whistles and rain clouds gallop across the sky. The 360-degree panoramic view must have impressed people 5,000 years ago as, towering over the vast landscape, they constructed the immense stone tomb, 60 metres in diameter.

Archaeologists have uncovered several tombs in the surrounding area, but deliberately left Maeve’s untouched. According to legend, the queen was buried standing upright with a sword, though no one has yet dared to open the burial mound.

That leaves the powerful legendary figure resting undisturbed in her Stone Age megalithic tomb, nourishing Ireland’s mythological heritage for the coming millennia.

Tuesday, September 29, 2026

 

Study: Obscure 1967 guide for LSD use still relevant as psychedelics gain in popularity


Survey participants agree with 18 of 19 tips from Lisa Bieberman, largely unknown acolyte of acid guru Timothy Leary



University at Buffalo



BUFFALO, N.Y. ­—  As psychedelic drugs such as LSD gain new momentum as a therapeutic treatment for severe post-traumatic stress disorder (PTSD), depression, and even headaches, a University at Buffalo researcher is exploring safety education for recreational users.

Daniel Kruger, PhD, research associate professor in the School of Public Health and Health Professions, looked back more than half a century for best practices on harm reduction.

In the 1960s, when Harvard psychology lecturer and psychedelics proponent Timothy Leary was advising people to “turn on, tune in, and drop out,” a young Radcliffe College graduate was quietly focused on another aspect of hallucinogens — safety.

Lisa Bieberman, who had been a Leary follower, established the Psychedelic Information Center in Cambridge, Mass. In February 1967, she published the $1 pamphlet, “Session Games People Play: A Manual for the Use of LSD,” which recommended best practices for the use of all types of psychedelics, especially for first-timers. She also addressed what might go wrong during an LSD or psilocybin ("magic”) mushroom trip.

“Bieberman highlights a number of games that may be better avoided during a LSD session, such as running away from your companions and believing that you have unlocked the deepest truths of the universe and need to tell the world about them,” Kruger says. “She also recommended that users stay with people they like and trust, avoid going out in public, and clear their minds of negative emotions.”

He launched a study with Paul Gillis-Smith, program lead at the Center for the Study of World Religious Studies at Harvard Divinity School, in which they surveyed almost 600 self-identified psychedelic users. Their findings, which showed that participants agreed with 18 of 19 pieces of Bieberman’s advice, were published in the Aug. 12 edition of the journal Psychedelics.

Other authors on the study are affiliated with the Michigan Psychedelic Center at the University of Michigan; Blue Sage Health Consulting in Ann Arbor, Mich., the Michigan Psychedelic Society; and the Radical Well-Being Center in Southfield, Mich.

When Kruger discovered Bieberman’s pragmatic teachings, which differed from Leary’s esoteric rhetoric, such as “surrender to the void,” he wanted to see if they would hold up today. It’s a timely inquiry, considering that psychedelic use now exceeds that of the counterculture ‘60s, according to Kruger.

Today, these drugs are gaining new momentum through hundreds of clinical trials and legal pathways in states like Oregon and Colorado, Kruger says.

“The idea is to medicalize these psychedelics for psychiatric conditions such as severe PTSD and depression,” he adds. “There really hasn’t been any big innovations in mental health medications since the selective serotonin reuptake inhibitors were introduced in the 1980s, and they don’t work as well as we originally thought.”

Psychedelics have even been used to treat physical conditions such as cluster headaches, which are so painful that some sufferers have reported suicidal ideation.

“The clinical trials show people are getting better for a range of conditions,” he says. “Some report finding more meaning in life, having greater spiritual connections, and improving their relationships.”

While these trials may offer promise to millions of  people, Kruger notes that the majority of those experimenting with psychedelics are doing so outside of a regulated context and with little prevention education.

 “As a public health professional, I believe we need to protect these users,” he says. “When Lisa’s pamphlet was published, there were few resources for novice users. Although the term ‘harm reduction’ was decades from entering the vernacular of drug use education and safety, we propose that ‘Session Games’ and Bieberman’s larger collection of work are precursors to this approach.”

The anonymous survey participants, who were recruited via online advertisements and in-person outreach at a psychedelic advocacy event in Ann Arbor, Mich., reported using LSD and psilocybin mushrooms, mescaline, ayahuasca, ketamine, and MDMA (ecstasy/molly), primarily within the last year. They ranged in age from 18 to 85, with an average age of 43. Some identified as psychedelic guides or educators.

In regard to how to best prepare for a psychedelic experience, the majority of respondents agreed with the statements: “Be with people who know, like, and trust each other,” and “Be aware that, even with a guide, you have to do most of the work yourself.”

For overall advice, the strongest agreement was with the statements, “Recognize that the experience will eventually end,” and “Recognize that you may experience anxiety, which does not mean that something is wrong.”

Participants neither uniformly agreed nor disagreed with the advice to avoid looking in the mirror during a psychedelic trip, which over the decades has proven to be a scary experience for some users.

“Participants strongly endorsed advice emphasizing interpersonal trust, personal responsibility and psychological preparation – principles thought to be foundations to safe and meaningful psychedelic experiences in clinical research,” Kruger says.

Indeed psychedelics were considered a promising therapeutic tool in the mid-20th century when they used to treat such conditions as neurosis and schizophrenia, along with general psychotherapy. However, by the late 1960s, drugs became criminalized and psychedelic therapy waned.

While classic psychedelic drugs are still illegal in the United States, Colorado and Oregon have established state-regulated frameworks for supervised therapeutic use. New Mexico is not far behind, says Kruger, who predicts that more psychedelics-based medications will enter the marketplace in the not-too-distant future.

“It’s a freight train coming down the tracks,” he says. “So, we better have a train station to safely load passengers into this train or else they’re just going to try to jump on board while this train is moving.”

Kruger notes that the 2026 Psychedelic Community Survey is now available for anyone to take, regardless if they have experienced psychedelics. While all answers are anonymous, he recommends that participants take the survey on a private computer or device in a private location.

 

Clinical trial tests psilocybin-assisted therapy for depression in advanced lung cancer patients



It’s the first trial specific to lung cancer using hallucinogenic mushroom-assisted therapy




Ohio State University Wexner Medical Center

Davis and Wagener

image: 

At The Ohio State University in Columbus, Ohio, Alan Davis, PhD (left) and Theodore Wagener, PhD (right) developed the first-ever clinical trial treating lung cancer patients with psilocybin-based therapy.

view more 

Credit: The Ohio State University Comprehensive Cancer Center






Nearly 40% of people with lung cancer experience depression, and many also face anxiety, hopelessness and questions about mortality after diagnosis. Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the Center for Psychedelic Drug Research and Education (CPDRE) in the College of Social Work (CSW) are leading a clinical trial to test whether psilocybin-assisted therapy can help reduce depression and emotional distress among patients with lung cancer.

An unmet mental health need

This new research addresses a pressing gap in cancer care: Many people with advanced lung cancer are living longer because of treatment advances, but depression, anxiety and distress can still affect daily life, relationships and the ability to cope with treatment.

This is the first study to test psilocybin-assisted therapy for depression specifically in people with lung cancer. The emotional strain can be especially intense for people with lung cancer, yet treatment options for cancer-related depression have changed little as cancer care has improved.

Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. In this study, it is given in a carefully controlled medical setting with counseling and support from trained therapists.

"There is growing evidence that psilocybin-assisted therapy may help relieve depression in people with cancer, but no study has focused specifically on patients with lung cancer," said Alan Davis, PhD, co-principal investigator of the study and directs Ohio State's Center for Psychedelic Drug Research and Education. "This is the first clinical trial designed to determine whether this approach can address the unique psychological challenges faced by this patient population."

"Many patients are diagnosed with advanced disease and are forced to confront questions about their future very quickly," said Theodore Wagener, PhD, co-principal investigator of the study and director of Ohio State's Center for Tobacco Research. Both Wagener and Davis are scientists with the OSUCCC – James Cancer Control Research Program. "Patients may experience anxiety, existential distress, loss of meaning and concerns about their families. Some also carry guilt tied to the stigma that can be associated with lung cancer."

Researchers say these emotional burdens can affect quality of life, daily routines, relationships and how patients experience cancer treatment.

Testing a guided treatment model

During this clinical trial, researchers will measure changes in depression and emotional well-being to learn whether the approach could offer another option for patients facing advanced cancer.

The trial combines psychotherapy with one supervised dose of psilocybin. Participants first complete about eight hours of preparation with two trained therapists. They then receive psilocybin during a daylong treatment session in a comfortable clinical setting, followed by counseling to help them process the experience.

"From the moment patients enter the study, they are paired with two therapists who support them throughout the entire process," Davis said. "The goal is to help participants feel safe, build trust and make sense of their experiences in ways that may improve their well-being."

Researchers also are studying whether psilocybin may affect inflammation, though more research is needed.

Looking beyond the cancer

For study participant Betty Paschall, the therapy was part of a turning point after a devastating diagnosis. Paschall was diagnosed with stage 4 lung cancer and initially felt overwhelmed by depression despite receiving treatment for her cancer.

"I didn't want to live," she said. "It was like I was the walking dead."

After participating in the study, Paschall said she noticed meaningful changes in her outlook and daily life. She began engaging in activities she had stopped doing and found herself reconnecting with the people and experiences that brought her joy.

"My sister and daughter both saw a difference in me," Paschall said. "I started to get back to myself a little more."

Researchers caution that psilocybin-assisted therapy remains experimental and is not appropriate for every patient. Participants undergo careful screening, and treatment is provided only under close medical supervision.

A successful study, investigators say, could help identify which patients are most likely to benefit and lay the groundwork for larger studies aimed at expanding treatment options for cancer-related depression.

"Cancer care has made major advances, but treatment for the depression, anxiety and distress that can come with advanced cancer has not moved as quickly," Wagener said. "We hope this research helps us better support the whole person, not just the cancer."

More Information 

Patients interested in being screened to participate in the study should contact Angela Douglas at douglas.496@osu.edu. To learn more about lung cancer treatment at the OSUCCC - James, visit cancer.osu.edu or call 1-800-293-5066.

Thursday, September 17, 2026

 

Can psychedelic clinical trials be better? Researchers say yes





University of California - San Francisco






UC San Francisco researchers are weighing in on one of the biggest challenges in psychedelic science, arguing that clinical trials need more convincing placebo treatments to better measure the drugs' true effects.

The debate hinges on "masking," the clinical trial gold standard that keeps patients and researchers from knowing who receives the active drug or a placebo. Because psychedelics produce such distinctive effects, participants can almost always tell whether they got the real thing. That makes it hard to separate a drug's effects from the power of expectation, including the disappointment patients feel when they realize they did not receive the psychedelic.

In a perspective published Sept. 16 in JAMA Psychiatry, researchers from UCSF, UC San Diego, and Stanford University call for a more aggressive approach to preserving masking in psychedelic clinical trials. The paper arrives as psychedelic research gains momentum and regulators face growing pressure to decide how these treatments should be evaluated and approved.

Instead of relying on active placebos such as niacin, which can cause flushing but little else resembling a psychedelic experience, the researchers propose carefully designed combinations of approved drugs to create a more convincing placebo. They also recommend limiting what participants are told about the study, making it harder to guess which treatment they received.

Psychedelics for serious mental illness have drawn growing interest because many patients do not respond to existing treatments. The authors argue that if researchers too readily accept failed masking as unavoidable, these compounds will never be rigorously tested.

"People say psychedelics can't be masked, so we should stop trying and just move on, because the effects are so obvious," said Josh D. Woolley, MD, PhD, associate professor in residence of psychiatry and behavioral sciences at UCSF and the paper's senior author. "But medicine has been fooled by obvious effects before. Heart stents for stable chest pain and knee arthroscopy for arthritis both looked effective until sham-controlled trials showed they weren't. We're excited about this paper because it outlines a novel approach that might finally make effective masking possible for psychedelics."

The proposed strategy, called UMBRAA, short for Unidentifiable Multidrug Blinding with Reduced, Authorized Awareness, combines giving carefully selected FDA-approved drugs with limited disclosure to study participants about what drugs they are receiving to make it harder for them to guess whether they are in the active treatment or the placebo-controlled arm of the study.

For example, a placebo might combine drugs from different classes, such as a sedative, a stimulant, and a cannabinoid. The researchers hypothesize that pairing drugs with different effects could create an intense, unfamiliar altered state that is harder to distinguish from psilocybin than current controls.

The researchers acknowledge that UMBRAA raises safety and ethical concerns and would require careful screening, close medical monitoring, and regulatory oversight.

They stress that the framework is a proposal, not a proven method. Future research will need to identify safe drug combinations, test whether they improve masking, and establish appropriate safeguards.

Authors: Other authors include Andrew Krystal, MD, PhD, of UCSF; Kevin H. Yang, MD, of UC San Diego; and Boris D. Heifets, MD, PhD, of Stanford University.

About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical system, includes top-ranked specialty hospitals  and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu. 

Wednesday, September 09, 2026

 

Psychedelics and anesthetics create mirror image patterns in the brain



A new study offers a data-driven approach to differentiating conscious state



Michigan Medicine - University of Michigan





For something so familiar to human experience, consciousness is still a mystery.

Each day, people cycle through wakefulness and sleep, from a higher level of consciousness to a lower one.

What’s more, some people alter their conscious experience with drugs such as psychedelics, or have unconsciousness induced by anesthesia.

Researchers have investigated these altered states of awareness in an attempt to understand how consciousness is organized within the brain.

A new Michigan Medicine led study takes a data driven approach and for the first time reveals that psychedelics and anesthetics create “mirror image” patterns of large-scale brain organization, with opposite network features.

The team, led by Rui Dai, Ph.D., and Zirui Huang, Ph.D., of the Department of Anesthesiology and Center for Consciousness Science at Michigan Medicine, analyzed functional MRI data from study participants who were administered psychedelic compounds—LSD, psilocybin and nitrous oxide—and compared them to readouts of MRIs of the brain in a sleeping state or under sedation with propofol.

“In previous literature, each individual drug’s influence on brain connectivity was analyzed separately,” said Dai.

“To our knowledge, no one has systematically assessed these two drug classes to compare network organization compared to waking consciousness.”

Specifically, the team observed that psychedelics increased functional connectivity (how closely two brain regions work together), while sleep and anesthesia reduced it.

The same pattern held for topological integration, meaning how easily information travels across the brain, and for interaction complexity, or the number of different patterns of brain interaction that can be observed.

“Overall, these results mean that during psychedelic states, the brain becomes more globally connected, more efficient in communication and more dynamic, while anesthetic states are the opposite,” said Dai.

Furthermore, their results offer a reliable way to differentiate conscious states using data.

The neural mechanism of consciousness is a longstanding scientific question, adds Huang, who is Director of the Center for Consciousness Science at University of Michigan Medical School.

“We analyze it using drugs because we know they will affect consciousness in some way, but we don’t know how. The mirror-image effect discovered by this study suggests that the integration, efficiency, and complexity of brain activity may be fundamental to consciousness.”

Additional authors: Hyunwoo Jang, Anthony G. Hudetz and George Mashour

Paper cited: “Opposite network patterns of integration-segregation in psychedelic and sedated states of consciousness,” Cell Reports. DOI: 10.1016/j.celrep.2026.117830